{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T01:57:04Z","timestamp":1789869424722,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Both mechanistic features and recent correlative findings suggest a potential role for protein kinase C-beta (PKC-\u03b2) in tumor pathogenesis, particularly in B-cell malignancies. To evaluate the role of this gene in lymphoid malignancies, we analyzed global gene expression data to quantify PKC-\u03b2 expression across diagnostic groups and, when possible, determined correlations between PKC-\u03b2 expression and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our analysis showed that the level of PKC-\u03b2 expression was highest in chronic lymphocytic leukemia and follicular lymphoma. Within diffuse large-B cell lymphoma (DLBCL), PKC-\u03b2 expression was significantly higher in activated B-cell- like subtype than germinal center B-cell- like subtype (<jats:italic>P<\/jats:italic>&lt; 0.0001). Elevated PKC-\u03b2 appeared to be associated with worse survival in both of these subtypes. When analyzed within clinically defined risk groups established by the International Prognostic Index (IPI), PKC-\u03b2 expression was lowest in patients with low IPI scores (0\u20131). Within intermediate- and high-risk IPI groups, elevated PKC-\u03b2 expression was associated with worse survival, suggesting that PKC-\u03b2 may expand the prognostic value of the IPI. Results of global gene expression analyses of DLBCL samples corroborate previous observations that anti-apoptosis, cell proliferation, and B-cell proliferation signaling pathways are functionally related to PKC-\u03b2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We present a first detailed pharmacogenomics report comparing PKC-\u03b2 mRNA expression across different lymphoid malignancies and evaluating it as an outcome predictor. Our findings suggest that DLBCL patients with elevated PKC-\u03b2 have a worse prognosis, indicating that further evaluation of PKC-\u03b2 as a chemotherapeutic target for lymphoid malignancies is warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Reviewers<\/jats:title><jats:p>This article was reviewed by Dr. Pierre Pontarotti, Dr. Kateryna Makova, and Dr. Matthew Coleman (nominated by Dr. Sandrine Dudoit).<\/jats:p><\/jats:sec>","DOI":"10.1186\/1745-6150-2-8","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T19:26:22Z","timestamp":1172085982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Retrospective analysis of protein kinase C-beta (PKC-\u03b2) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas"],"prefix":"10.1186","volume":"2","author":[{"given":"Shuyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Phong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Brail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris K","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,21]]},"reference":[{"key":"47_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0306-3623(98)00069-X","volume":"31","author":"A Gescher","year":"1998","unstructured":"Gescher A: Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 1998, 31: 721-728.","journal-title":"Gen Pharmacol"},{"key":"47_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1126\/science.1411571","volume":"258","author":"Y Nishizuka","year":"1992","unstructured":"Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258: 607-614. 10.1126\/science.1411571","journal-title":"Science"},{"key":"47_CR3","first-page":"4413","volume":"59","author":"H Yoshiji","year":"1999","unstructured":"Yoshiji H, Kuriyama S, Ways D, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, Fukui H: Protein kinase C lies in the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999, 59: 4413-4418.","journal-title":"Cancer Res"},{"key":"47_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1023\/A:1007177806496","volume":"17","author":"HB Guo","year":"2000","unstructured":"Guo HB, Shen ZH, Huang CX, Ma J, Huang Y, Chen HL: Modulation of the basal activity of phosphatidylinositol-3-kinase\/protein kinase B signaling pathway in human hepatocarcinoma cells. Glycoconj J 2000, 17: 315-322. 10.1023\/A:1007177806496","journal-title":"Glycoconj J"},{"issue":"Suppl 1","key":"47_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.5-suppl_1-3","volume":"5","author":"G McMahon","year":"2000","unstructured":"McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist 2000,5(Suppl 1):3-10. 10.1634\/theoncologist.5-suppl_1-3","journal-title":"Oncologist"},{"key":"47_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1006\/bbrc.1997.7327","volume":"238","author":"A Sawano","year":"1997","unstructured":"Sawano A, Takahashi T, Yamaguchi S, Shibuya M: The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLC\u03b3. Bioch Biophys Res Commun 1997, 238: 487-491. 10.1006\/bbrc.1997.7327","journal-title":"Bioch Biophys Res Commun"},{"key":"47_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1172\/JCI119006","volume":"98","author":"P Xia","year":"1996","unstructured":"Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996, 98: 2018-2026.","journal-title":"J Clin Invest"},{"key":"47_CR8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1126\/science.273.5276.788","volume":"273","author":"M Leitges","year":"1996","unstructured":"Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, Tarakhovsky A: Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996, 273: 788-791. 10.1126\/science.273.5276.788","journal-title":"Science"},{"key":"47_CR9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/ni823","volume":"3","author":"TT Su","year":"2002","unstructured":"Su TT, Guo B, Kawakami Y, Sommer , Chae K, Humphries LA, Kato RM, Kang S, Patrone L, Wall R, Teitell M, Leitges M, Kawakami T, Rawlings DJ: PKC-\u03b2 controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002, 3: 780-786.","journal-title":"Nat Immunol"},{"key":"47_CR10","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.4049\/jimmunol.162.5.2655","volume":"62","author":"LB King","year":"1999","unstructured":"King LB, Norvell A, Monroe JG: Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells. J Immunol 1999, 62: 2655-2662.","journal-title":"J Immunol"},{"key":"47_CR11","doi-asserted-by":"crossref","first-page":"427a","DOI":"10.1182\/blood.V106.11.427.427","volume":"106","author":"R Rossi","year":"2005","unstructured":"Rossi R, Henn AD, Conkling R, Guzman ML, Bushnell T, Harvey J, Fisher RI, Jordan CT: The PKC-\u03b2 selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells [abstract]. Blood 2005, 106: 427a.","journal-title":"Blood"},{"key":"47_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm0102-68","volume":"8","author":"MA Shipp","year":"2002","unstructured":"Shipp MA, Ross K, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8: 68-74. 10.1038\/nm0102-68","journal-title":"Nat Med"},{"key":"47_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329: 987-994. 10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"47_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403: 503-511. 10.1038\/35000501","journal-title":"Nature"},{"key":"47_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma\/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl Med 2002, 346: 1937-1947. 10.1056\/NEJMoa012914","journal-title":"N Engl Med"},{"key":"47_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Amer Stat Assoc 1958, 53: 457-481. 10.2307\/2281868","journal-title":"J Amer Stat Assoc"},{"key":"47_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.V104.11.3258.3258","volume":"104","author":"I Espinosa","year":"2004","unstructured":"Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J: PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with low risk diffuse large B-cell lymphoma [abstract]. Blood 2004, 104: 293.","journal-title":"Blood"},{"key":"47_CR18","doi-asserted-by":"publisher","first-page":"224b","DOI":"10.1182\/blood-2003-07-2461","volume":"104","author":"R Schaffel","year":"2004","unstructured":"Schaffel R, Biasoli I, Scheliga A, Morais JC, Romano S, Pulcheri W, Spector N: The expression of protein kinase C beta II (PKC\u03b2) by immunocytochemistry is predictive of the disease free survival (DFS) in diffuse large B-cell lymphoma (DLBCL) [abstract]. Blood 2004, 104: 224b. 10.1182\/blood-2003-07-2461","journal-title":"Blood"},{"key":"47_CR19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/modpathol.3800434","volume":"18","author":"CP Hans","year":"2005","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, Pan Z, Smith LM, Lynch JC, Bociek RG, Bierman PJ, Vose JM, Armitage JO: Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005, 18: 1377-1384. 10.1038\/modpathol.3800434","journal-title":"Mod Pathol"},{"key":"47_CR20","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","volume":"65","author":"JR Graff","year":"2005","unstructured":"Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D: The protein kinase C\u03b2-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005, 65: 7462-7469. 10.1158\/0008-5472.CAN-05-0071","journal-title":"Cancer Res"},{"key":"47_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.yjmcc.2005.06.016","volume":"39","author":"J-Y Lim","year":"2005","unstructured":"Lim J-Y, Park SJ, Hwang H-Y, Park EJ, Nam JH, Kim J, Park SI: TGF-\u03b21 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol 2005, 39: 627-636. 10.1016\/j.yjmcc.2005.06.016","journal-title":"J Mol Cell Cardiol"},{"key":"47_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Ser B (Statistical Methodology) 1995, 57: 289-300.","journal-title":"J R Stat Soc: Ser B (Statistical Methodology)"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6150-2-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:22:21Z","timestamp":1736814141000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologydirect.biomedcentral.com\/articles\/10.1186\/1745-6150-2-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,21]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1186\/1745-6150-2-8","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,21]]},"assertion":[{"value":"13 February 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"8"}}